Joam Mattheus Adami

Adamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects

Retrieved on: 
Wednesday, September 21, 2022

The DSMB did note that no safety concerns were identified in the subjects that received Tempol.

Key Points: 
  • The DSMB did note that no safety concerns were identified in the subjects that received Tempol.
  • We are obviously disappointed that the study did not meet its endpoints, said Ron Moss, MD, Chief Medical Officer of Adamis.
  • I would like to thank our clinical research partners, the trial investigators and all the trial subjects for their participation.
  • Tempol is in development for the treatment of patients with COVID-19 and a Phase 2/3 clinical trial has been conducted.

Adamis Provides an Enrollment Update on the Phase 2/3 Study of Tempol in COVID-19 Positive High-Risk Subjects

Retrieved on: 
Monday, September 12, 2022

SAN DIEGO, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the Company’s ongoing U.S. Phase 2/3 clinical trial to evaluate the safety and efficacy of Tempol as a treatment for COVID-19 has reached the initial planned enrollment of 248 subjects.

Key Points: 
  • Phase 2/3 clinical trial to evaluate the safety and efficacy of Tempol as a treatment for COVID-19 has reached the initial planned enrollment of 248 subjects.
  • This interim meeting is significant as it will mark the first time the DSMB evaluates statistical measures of efficacy for Tempol.
  • Eligible subjects with positive COVID-19 infection within five days of study entry plus at least one co-morbidity were randomized one-to-one to receive either Tempol or placebo.
  • Tempol is in development for the treatment of patients with COVID-19 and a Phase 2/3 clinical trial is underway.

Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19

Retrieved on: 
Friday, July 29, 2022

SAN DIEGO, July 29, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the Companys ongoing U.S.

Key Points: 
  • SAN DIEGO, July 29, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the Companys ongoing U.S.
  • Phase 2/3 clinical trial to evaluate the safety and efficacy of Tempol as a treatment for COVID-19.
  • If positive trends are observed in favor of the Tempol treatment group, the DSMB may recommend continuing the study along with the enrollment of additional subjects.
  • Tempol is in development for the treatment of patients with COVID-19 and a Phase 2/3 clinical trial is underway.

Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19

Retrieved on: 
Wednesday, June 1, 2022

Based on an interim review of the data, the DSMB determined that the study can continue as planned.

Key Points: 
  • Based on an interim review of the data, the DSMB determined that the study can continue as planned.
  • We look forward to the completion and final analysis of this important clinical trial, said David J. Marguglio, Chief Executive Officer of Adamis Pharmaceuticals.
  • The Company previously announced the results of a published study in collaboration with Stanford University researchers, suggesting that Tempol has strong, broad in-vitro anti-cytokine activity.
  • Tempol is in development for the treatment of patients with COVID-19 and a Phase 2/3 clinical trial is underway.

Adamis Pharmaceuticals Announces Results of Tempol in Omicron Virus Challenge in Hamster Model

Retrieved on: 
Tuesday, March 22, 2022

Dr. Chien-Te Kent Tseng, Professor in the Department of Microbiology and Immunology and Director of GNLs SARS/MERS/COVID-19 Laboratory at UTMB, commented on these results: In our hamster model using high doses of omicron virus, we observe significant pulmonary inflammation.

Key Points: 
  • Dr. Chien-Te Kent Tseng, Professor in the Department of Microbiology and Immunology and Director of GNLs SARS/MERS/COVID-19 Laboratory at UTMB, commented on these results: In our hamster model using high doses of omicron virus, we observe significant pulmonary inflammation.
  • Tempol acts as a potent anti-inflammatory in the hamster challenge model, which we believe is an appropriate model for human COVID-19.
  • Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis Pharmaceuticals commented: The new Omicron variant BA.2 is predicted to increase in the US over the next few weeks.
  • The recent Tempol animal study shows significant decrease in lung inflammation in hamsters given high doses of Omicron.

Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19

Retrieved on: 
Monday, March 14, 2022

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease.

Key Points: 
  • Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease.
  • The Companys SYMJEPI (epinephrine) Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
  • Tempol is in development for the treatment of patients with COVID-19 and a Phase 2/3 clinical trial is underway.
  • For additional information about Adamis Pharmaceuticals, please visit www.adamispharmaceuticals.com and follow us on Twitter and LinkedIn .